Atalanta Therapeutics

Industry

  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Antisense, Oligonucleotides
See more in Biomedtracker

Latest on Atalanta Therapeutics

Scrip

Finance Watch: Abcuro Raises $200m To See Lead Drug Through To Launch

 
• By Mandy Jackson

Abcuro Inc.’s venture capital investors showed confidence in the ongoing Phase II/III MUSCLE clinical trial of ulviprubart (ABC008) in inclusion body myositis (IBM) by putting their support behind a $

Scrip

Atalanta Raises $97m To Advance RNAi Therapies For Epilepsy And Huntington’s

 
• By Andrew McConaghie

Atalanta Therapeutics has raised $97m in a series B financing to help it bring its RNA interfering therapies for CNS diseases into their first clinical trials. The Boston, MA-based biotech is built on

Scrip

Already Number One In Neuroscience, Roche Extends Ionis RNA Partnership To Tackle Alzheimer’s And Huntington’s

 
• By Andrew McConaghie

While Roche is still probably best known for its leading position in oncology, the Swiss pharma company has in recent years become the world’s biggest neuroscience company based on revenues. That is

Scrip

Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip

 
• By Alaric DeArment

Notwithstanding a three-month delay in a US Food and Drug Administration verdict, Biogen, Inc. is including the Alzheimer’s disease drug aducanumab in its 2021 guidance as dampened sales of its appr